Annual report pursuant to Section 13 and 15(d)

Fair Value Measurements - Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation (Details)

v3.8.0.1
Fair Value Measurements - Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2017
USD ($)
Beginning Balance $ 7,514
Initial Liability 2,877
Payments (260) [1]
Accretion 122
Cancellation of Obligation/Conversions Exercises (8,575)
Adjustment to fair value/Mark to Market 376
Ending Balance 2,054
Pre-Funded Warrants [Member]  
Beginning Balance
Initial Liability 2,247
Payments [1]
Accretion
Cancellation of Obligation/Conversions Exercises (2,337)
Adjustment to fair value/Mark to Market 90
Ending Balance
Underwriter Warrants[Member]  
Beginning Balance
Initial Liability 422
Payments [1]
Accretion
Cancellation of Obligation/Conversions Exercises
Adjustment to fair value/Mark to Market 51
Ending Balance 473
Asuragen [Member]  
Beginning Balance 1,545
Payments (260) [1]
Accretion 122
Cancellation of Obligation/Conversions Exercises
Adjustment to fair value/Mark to Market 174
Ending Balance 1,581
RedPath [Member]  
Beginning Balance 5,969
Payments [1]
Accretion
Cancellation of Obligation/Conversions Exercises (5,969)
Adjustment to fair value/Mark to Market
Ending Balance
Embedded Conversion Option [Member]  
Beginning Balance
Initial Liability 208
Payments [1]
Accretion
Cancellation of Obligation/Conversions Exercises (269)
Adjustment to fair value/Mark to Market 61
Ending Balance
[1] Royalty payments of $235,000 are reflected within Cash Flows from Operations. The remaining $25,000 represents a milestone payment related to financing the Asuragen acquisition and is reflected in Cash Flows from Financing Activities.